The KERENDIA Patient Support Program offers savings and support options to help eligible patients start and stay on KERENDIA

safety-and-support-money-icon

Your eligible patients may pay as little as $10 per month for KERENDIA.*

It is easy to get or activate a savings card. Your patients may:

Savings icon

Your eligible patients may pay as little as $10 per month for KERENDIA.*

It is easy to get or activate a savings card. Your patients may:

*Eligible patients may pay as little as $10 and save up to $3000 per year. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. Full terms and conditions apply.
By texting SAVE to 53736 to enroll or activate your card, you agree to receive recurring automated KERENDIA (finerenone) Co-pay Savings Program messages, which may include savings alerts, refill reminders, and other messages related to your participation in the co-pay program. Consent to receiving SMS messages is not a condition of purchase of goods or services. Message and data rates may apply. Message frequency varies. Text STOP to opt out. Text HELP for help. Terms & Conditions and Privacy Policy apply. For T&C, click here. For Privacy Policy, click here. For SMS Terms, click here.

Access Services by BayerTM is working with CoverMyMeds® to provide the support your patients count on—with enhanced services you can trust from CoverMyMeds®

We provide visibility into the entire patient journey that reduces time to therapy through enhanced services within your workflow:

  • Electronic Benefits Verification (eBV), Benefits Investigation
  • Electronic Prior Authorization (ePA)
  • Appeals support
  • Bridge program for eligible patients*

Do you already use CoverMyMeds®? Log in to the portal at CoverMyMeds.com to enroll your patients today.

Would you like to learn more? Download the CoverMyMeds® brochure for additional information.

If you and your patients are not able to use CoverMyMeds®, please use these resources to advocate for patients with insurance, or contact Access Services by BayerTM for support at 1-800-288-8374.

*Patients eligible if formulary coverage determination has not been made or they are experiencing delays in PA processing.

 

Medisafe is a registered trademark of Medisafe Project LTD.

Personalized Patient Support

The KERENDIA Patient Support Program includes access to a personal mentor who can provide support and educational resources during patients’ first months on KERENDIA. Patients can choose whether they would like to communicate with their personal mentor by phone, email, or text. To sign up visit KERENDIA.com.

Patients can get help managing their KERENDIA treatment with the KERENDIA Digital Companion on Medisafe

The KERENDIA Digital Companion is available for free on the Medisafe app. This tool helps patients manage their treatment by providing customized medication and appointment reminders, treatment and condition-related information, and more.

Patients can download the Medisafe app for free from their app store.

Explore FAQs and resources for your patients

Bayer US Patient Assistance Foundation

Assistance representative icon

Do you have a patient who needs additional assistance?

Do you have a patient who needs additional assistance?

 

The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please have your patient contact the program at 1-866-2BUSPAF (228-7723). Monday–Friday, 9:00 am–6:00 pm EST, or visit the foundation website at www.patientassistance.bayer.us to see if they might qualify for assistance.

 

The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please have your patient contact the program at 1-866-2BUSPAF (228-7723). Monday–Friday, 9:00 am–6:00 pm EST, or visit the foundation website at www.patientassistance.bayer.us to see if they might qualify for assistance.

IMPORTANT SAFETY INFORMATION AND INDICATION

INDICATION:

  • KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)

CONTRAINDICATIONS:

  • Concomitant use with strong CYP3A4 inhibitors
  • Patients with adrenal insufficiency

WARNINGS AND PRECAUTIONS:

  • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L

     

    Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium

MOST COMMON ADVERSE REACTIONS:

  • Adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo: hyperkalemia (18.3% vs. 9%), hypotension (4.8% vs. 3.4%), and hyponatremia (1.4% vs. 0.7%)

DRUG INTERACTIONS:

  • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
  • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
  • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers

USE IN SPECIFIC POPULATIONS:

  • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
  • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)

INDICATION:

  • KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)

Please read the Prescribing Information for KERENDIA.

Reference:

  • KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; July 2021. Return to content